Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 195

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 195
---
 laboratory information management systems. As part of these restructurings, we had long-lived assets that were no longer being utilized and we vacated certain leased space in South San Francisco, California. As such, we assessed the related assets for impairment by first comparing their carrying amounts to the future net undiscounted cash flows projected to be generated over their remaining lease terms or depreciable lives, as applicable. The carrying amounts were all found to be unrecoverable, thus we assessed the fair values of the assets. The extent to which the carrying amounts of the assets exceed their fair values represents the impairment costs to be recognized. As a result of our assessments, we recognized $7.2 million of impairment charges. Of the $7.2 million charges recognized, $1.1 million and $3.3 million relates to the right-of-use asset and related long-lived assets (namely laboratory equipment and leasehold improvements), respectively, associated with certain of our leased space in South San Francisco, California. The remaining $2.8 million recognized relates to the impairment of long-lived assets associated with our halted software enhancements. We also incurred an additional $0.7 million in restructuring costs primarily related to one-time termination benefits and ongoing benefit arrangements.During the six months ended December 31, 2024, we incurred an additional $0.3 million in aggregate restructuring costs, which primarily related to one-time termination benefits and ongoing benefit arrangements.In total, we recognized restructuring costs of $9.2 million during the year ended December 31, 2024. The activities and payments related to these restructurings were completed and paid as of December 31, 2024.

16.Income TaxesThe components of loss before provision for income taxes for the periods presented were as follows (in thousands): 

        Year Ended December 31,

        2024

        2023

        2022

        Domestic
         
        $
        (159,635
        )
         
        $
        (225,335
        )
         
        $
        (200,427
        )

        Foreign

        40

        31

        59

        Total loss before provision for income taxes
         
        $
        (159,595
        )
         
        $
        (225,304
        )
         
        $
        (200,368
        )

115

Adaptive Biotechnologies CorporationNotes to Consolidated Financial Statements (Continued) 

Deferred income taxes reflect the